

Paper No. \_\_\_\_  
Filed: May 31, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,  
INC. and AKORN INC.,  
Petitioners,

v.

ALLERGAN, INC.  
Patent Owner.

---

Case IPR2016-01130  
Patent No. 8,633,162 B2

---

**PETITIONER MYLAN PHARMACEUTICALS INC.'S MANDATORY  
CHANGE-OF-INFORMATION NOTICES**

Case IPR2016-01130  
Patent 8,633,162 B2

Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”), hereby submits the following mandatory change-of-information notices in connection with the petition for *inter partes* review of U.S. Patent No. 8,633,162 B2, Case IPR2016-01130.

- A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged**
- B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Unchanged**
- C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Revised**

Mylan provides the following updated designation of counsel:

<b>Lead Counsel</b>	<b>Back-Up Counsel</b>
Steven W. Parmelee	Michael T. Rosato
USPTO Reg. No. 31,990	USPTO Reg. No. 52,182
WILSON SONSINI GOODRICH & ROSATI	WILSON SONSINI GOODRICH & ROSATI
701 Fifth Avenue, Suite 5100	701 Fifth Avenue, Suite 5100
Seattle, WA 98104-7036	Seattle, WA 98104-7036
Tel.: 206-883-2542	Tel.: 206-883-2529
Fax: 206-883-2699	Fax: 206-883-2699
Email: sparmelee@wsgr.com	Email: mrosato@wsgr.com

Case IPR2016-01130  
Patent 8,633,162 B2

<b>Back-Up Counsel</b>	<b>Back-Up Counsel</b>
Jad A. Mills  USPTO Reg. No. 63,344  WILSON SONSINI GOODRICH & ROSATI  701 Fifth Avenue, Suite 5100  Seattle, WA 98104-7036  Tel.: 206-883-2554  Fax: 206-883-2699  Email: jmills@wsgr.com	Wendy L. Devine  USPTO Reg. No. 61,309  WILSON SONSINI GOODRICH & ROSATI  One Market Street,  Spear Tower Floor 33  San Francisco, CA 94105-1126  Tel.: 858-350-2321  Fax: 415-947-2099  Email: wdevine@wsgr.com

**D. Electronic Service**

Mylan consents to electronic service by email at the email addresses provided above.

Respectfully submitted,

Dated: May 31, 2017

/ Steven W. Parmelee /  
\_\_\_\_\_  
Steven W. Parmelee  
Reg. No. 31,990

Case IPR2016-01130  
Patent 8,633,162 B2

CERTIFICATE OF SERVICE

This is to certify that I caused to be served a true and correct copy of the foregoing Petitioner Mylan Pharmaceuticals Inc.'s Mandatory Change-of-Information Notices on this 31<sup>st</sup> day of May, 2017, on the Patent Owner at the correspondence address of the Patent Owner as follows:

Dorothy P. Whelan  
Michael Kane  
Susan Morrison Colletti  
Robert M. Oakes  
Jonathan Singer  
Fish & Richardson P.C.  
3200 RBC Plaza  
60 South Sixth Street  
Minneapolis, MN 55402  
Email: [IPR13351-0008IP1@fr.com](mailto:IPR13351-0008IP1@fr.com)  
Email: [IPR13351-0008IP2@fr.com](mailto:IPR13351-0008IP2@fr.com)  
Email: [IPR13351-0008IP3@fr.com](mailto:IPR13351-0008IP3@fr.com)  
Email: [IPR13351-0008IP4@fr.com](mailto:IPR13351-0008IP4@fr.com)  
Email: [IPR13351-0008IP5@fr.com](mailto:IPR13351-0008IP5@fr.com)  
Email: [IPR13351-0008IP6@fr.com](mailto:IPR13351-0008IP6@fr.com)  
Email: [PTABInbound@fr.com](mailto:PTABInbound@fr.com)

And on the remaining petitioners as follows:

Gary Speier  
Mark Schuman  
CARLSON, CASPERS, VANDENBURGH,  
LINDQUIST & SCHUMAN, P.A.  
225 South Sixth Street, Suite 4200  
Minneapolis, MN 55402  
Email: [gspeier@carlsoncaspers.com](mailto:gspeier@carlsoncaspers.com)  
Email: [mschuman@carlsoncaspers.com](mailto:mschuman@carlsoncaspers.com)  
*Attorneys for Teva Pharmaceuticals USA, Inc.*

Case IPR2016-01130

Patent 8,633,162 B2

Michael Dzwonczyk

Azadeh Kokabi

Travis Ribar

SUGHRUE MION, PLLC

2100 Pennsylvania Ave., NW

Washington, DC 20037

Email: [mdzwonczyk@sughrue.com](mailto:mdzwonczyk@sughrue.com)

Email: [akokabi@sughrue.com](mailto:akokabi@sughrue.com)

Email: [tribar@sughrue.com](mailto:tribar@sughrue.com)

*Attorneys for Akorn Inc.*

Respectfully submitted,

Dated: May 31, 2017

/ Steven W. Parmelee /

Steven W. Parmelee, Lead Counsel

Reg. No. 31,990